



May 4, 2010

## **PDL BioPharma to Present at Ninth Annual JMP Securities Research Conference on May 12, 2010**

INCLINE VILLAGE, Nev., May 4, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Ninth Annual JMP Securities Research Conference in San Francisco on Wednesday, May 12, 2010 at 9:00 a.m. Pacific Time.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at <http://www.pdl.com> and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available through May 13, 2010.

### **About PDL BioPharma**

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit [www.pdl.com](http://www.pdl.com).

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.